Bolt Biotherapeutics (BOLT)
(Delayed Data from NSDQ)
$0.59 USD
-0.01 (-1.87%)
Updated Sep 25, 2024 03:59 PM ET
After-Market: $0.59 0.00 (0.61%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
BOLT 0.59 -0.01(-1.87%)
Will BOLT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BOLT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BOLT
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
BOLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates
Other News for BOLT
Bolt Metals Expands Mining Property Amid Supply Concerns
Bolt Biotherapeutics Announces Changes to its Board of Directors
Bolt Metals Welcomes New CEO Branden Haynes
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment
Bolt Biotherapeutics names Brian O'Callaghan chairman